

1 **Primary series and booster COVID-19 vaccine effectiveness in a cohort of healthcare workers in**
2 **Albania during a BA.1 and BA.2 variant period, January – May 2022**

3 **Authors:** Iris Finci^{1*}, Madelyn Yiseth Rojas Castro^{2*}, Iris Hasibra³, Jonilda Sulo^{4,5}, Albana Fico³, Rovena
4 Daja³, Adela Vasili³, Majlinda Kota³, Iria Preza⁶, Barbara Mühlemann^{7,8}, Christian Drosten^{7,8}, Richard
5 Pebody¹, Kathryn E. Lafond⁹, Esther Kissling², Mark A. Katz¹, Silvia Bino^{3,4}

6 ¹World Health Organization Regional Office for Europe, Copenhagen, Denmark

7 ²Epiconcept, Paris, France

8 ³Institute of Public Health, Tirana, Albania

9 ⁴Southeast European Center for Surveillance and Control of Infectious Disease, Tirana, Albania

10 ⁵Mediterranean and Black Sea Programme in Intervention Epidemiology Training (MediPIET), European
11 Centre for Disease Prevention and Control (ECDC), Solna, Sweden

12 ⁶World Health Organization, Country Office Albania, Tirana, Albania

13 ⁷Institute of Virology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
14 Humboldt- Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany

15 ⁸German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany

16 ⁹Influenza Division, US Centers for Disease Control, Atlanta, Georgia

17 *These authors contributed equally

18

19 Corresponding author:

20 Silvia Bino, MD, PhD

21 silviabino@gmail.com

22

23 Abstract word count: 242

24 Manuscript word count: 3447

25 **Abstract**

26 *Background*

27 Healthcare workers (HCWs) have experienced high rates of COVID-19 morbidity and mortality. We
28 estimated COVID-19 two-dose primary series and monovalent booster vaccine effectiveness (VE) against
29 symptomatic SARS-CoV-2 Omicron (BA.1 and BA.2) infection among HCWs in three Albanian hospitals
30 during January–May 2022.

31

32 *Methods*

33 Study participants completed weekly symptom questionnaires, underwent PCR testing when
34 symptomatic, and provided quarterly blood samples for serology. We estimated VE using Cox regression
35 models (1-hazard ratio), with vaccination status as the time-varying exposure and unvaccinated HCWs as
36 the reference group, adjusting for potential confounders: age, sex, prior SARS-CoV-2 infection (detected
37 by PCR, rapid-antigen test or serology), and household size.

38

39 *Results*

40 At the start of the analysis period, 76% of 1,462 HCWs had received a primary series, 10% had received a
41 booster dose, and 9% were unvaccinated; 1,307 (89%) HCWs had evidence of prior infection. Overall,
42 86% of primary series and 98% of booster doses received were BNT162b2. The median time interval
43 from the second dose and the booster dose to the start of the analysis period was 289 days (IQR:210–
44 292) and 30 days (IQR:22–46), respectively. VE against symptomatic PCR-confirmed infection was 34%
45 (95%CI: -36;68) for the primary series and 88% (95%CI: 38;98) for the booster.

46

47 *Conclusions*

48 Among Albanian HCWs, most of whom had been previously infected, COVID-19 booster dose offered
49 improved VE during a period of Omicron BA.1 and BA.2 circulation. Our findings support promoting
50 booster dose uptake among Albanian HCWs, which, as of January 2023, was only 20%.

51

52

53

54 Introduction

55 Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19
56 pandemic^{1,2}. Vaccinating HCWs against COVID-19 decreases COVID-19-related illness and absenteeism
57 and therefore helps to maintain a functioning health care workforce during periods of high burden on
58 health systems. Additionally, vaccinating HCWs can potentially reduce onward SARS-CoV-2
59 transmission³. Understanding COVID-19 vaccine effectiveness (VE) among HCWs is critical to inform
60 optimal vaccination policies.

61 As of February 2023, in the European Region of the World Health Organization (WHO), primary series
62 and booster COVID-19 vaccine uptake among HCWs was considerably lower in the 5/19 middle-income
63 countries (MICs) that reported data to WHO (66% and 27%, respectively) compared to the 20/34 high
64 income countries (HICs) that reported (82% and 59%, respectively)⁴.

65 Few COVID-19 VE studies have been reported in MICs in Europe or globally, particularly during periods
66 of Omicron circulation⁵. Differences in population health and demographics, differences in health
67 systems and time of access to COVID-19 vaccines between HICs and MICs may variably impact vaccine
68 performance, underscoring the need for VE studies in MICs to guide policy⁶. Furthermore, local data
69 demonstrating positive VE estimates can be helpful in promoting vaccine uptake in countries where
70 vaccine acceptance is low.

71 In early 2022, the spread of SARS-CoV-2 Omicron, a variant with higher transmissibility compared to
72 previous variants⁷, led to elevated pressure on healthcare systems across Europe, and many infected
73 HCWs missed work⁸. To date, studies of COVID-19 VE against Omicron, mostly from HICs⁹, have shown
74 sustained moderate to high primary series VE against severe disease (76% within 6 months after the last

75 dose) but much lower VE against milder symptomatic infection (35% within 6 months after last dose)¹⁰;
76 however, VE estimates against mild infection increased to 62%¹¹ and 71%¹⁰ following booster doses.

77 In Albania, an upper-MIC of 2.8 million inhabitants in Southeast Europe, COVID-19 vaccination with
78 BNT162b2 (Comirnaty, Pfizer-BioNTech) started on 11 January 2021, and HCWs were a high-priority
79 group for vaccination. Additionally, ChAdOx1-S (Vaxzervria, AstraZeneca) and CoronaVac (Sinovac Life
80 Sciences) were introduced in mid-March 2021. On 15 October 2021, the Albanian National Technical
81 Advisory Group for Immunizations recommended a booster vaccine for all HCWs who had completed
82 their primary series at least six months prior. As of 31 January 2023, while most Albanian HCWs (83%)
83 had received primary series vaccine, only 20% had received a booster (third) dose⁴.

84 In February 2021, we established a cohort of HCWs in Albania to prospectively monitor COVID-19 VE
85 against SARS-CoV-2 infection¹²⁻¹⁴. In this analysis, we evaluated primary series and booster dose VE
86 against SARS-CoV-2 infection during BA.1 and BA.2 Omicron period.

87 **Methods**

88 *Study Design*

89 We conducted an interim analysis of an ongoing prospective cohort study that started in February 2021.
90 Our objective was to estimate VE of COVID-19 primary vaccine series and booster dose against
91 symptomatic and asymptomatic SARS-CoV-2 infection among HCWs at three hospitals in Albania, from
92 January through May 2022. Study methods and early primary series VE results have been previously
93 published^{12,14}.

94 *Data Collection*

95 At enrolment (February–May 2021), participants completed a questionnaire that included questions
96 about demographics, health status, hospital role and prior COVID-19 vaccination. During the study,
97 participants completed weekly symptom questionnaires; participants who reported having any
98 symptom included in the Albanian MOH COVID-19 case definition¹² provided a nasopharyngeal
99 specimen that was tested for SARS-CoV-2 by RT-PCR at the Institute of Public Health Laboratory in
100 Tirana, Albania.

101 Study staff cross-checked the Albanian National Surveillance of Infectious Diseases Electronic
102 Information System (SISI) to identify any PCR or rapid antigen tests (RATs) performed in laboratories and
103 hospitals outside of the study, and entered these data into the study database. Self-tested RAT results
104 were not recorded. Participants who tested positive for SARS-CoV-2 by PCR or RAT were administered a
105 follow-up questionnaire about their course of illness 30 days after their positive test. Study staff verified
106 participants' COVID-19 vaccination status through the national integrated immunization information
107 system (IIS) and the family care physicians web-based medical data system (E-vizita). All study data were
108 entered securely and stored in REDCap¹⁵.

109 *Laboratory procedures*

110 We collected blood specimens from participants at enrolment and then every three months throughout
111 the study. Specimens were tested for total anti-nucleocapsid antibody using the Platelia SARS-CoV-2
112 Total Antibody Assay (Bio-Rad Laboratories, Hercules, CA). Cut-off values were determined according to
113 instructions from the package insert

114 PCR-positive specimens were sent to the Institute of Virology – Charité (Berlin, Germany), where a
115 representative subset of specimens based on dates and location and cycle threshold value below 24 was

116 selected to undergo whole genome sequencing (WGS). We also inspected Albanian molecular
117 surveillance data from the Global Initiative on Sharing All Influenza Data (GISAID)¹⁶.

118

119 *Vaccine effectiveness analysis*

120 We measured primary series and booster dose VE compared to unvaccinated participants. Additionally,
121 we measured the relative VE (rVE) of booster dose, comparing HCWs who received primary series and
122 booster dose vaccination with HCWs who received primary series alone. For both VE and rVE, the
123 primary analytic outcome was PCR-confirmed symptomatic SARS-CoV-2 infection. For the booster dose
124 VE analyses, HCWs started contributing person-time only when they were eligible to receive the booster
125 dose. We also measured VE against two secondary outcomes: an outcome of any PCR- or RAT-confirmed
126 symptomatic SARS-CoV-2 infection, , and a combined outcome of symptomatic and asymptomatic SARS-
127 CoV-2 infection, confirmed by one of three tests: PCR, RAT, and/or seroconversion. Because inactivated
128 vaccines can produce anti-nucleocapsid antibodies, we excluded participants who received CoronaVac
129 from the analysis that included seroconversion as an endpoint. We defined a symptomatic SARS-CoV-2
130 infection as a participant with symptom onset between 14 days before and 4 days after the collection
131 date of a SARS-CoV-2-positive swab. We defined seroconversion as a positive anti-nucleocapsid antibody
132 test preceded by a negative anti-nucleocapsid antibody test 3 months earlier.

133 For participants who seroconverted without having a positive PCR test or RAT, we estimated the date of
134 infection using two approaches; for participants who reported symptoms on their weekly questionnaire
135 during the period of seroconversion, the inferred date of infection was the date of symptom onset. For
136 those without reported symptoms, we estimated the date of infection as the mid-point between the last
137 negative serological test and the date three weeks before the subsequent positive serological test¹⁷.

138 We defined prior infection as a history of a positive PCR test, RAT or anti-nucleocapsid serology test at
139 the start of the analysis period. For each analysis described above, we also conducted stratified analyses
140 to evaluate VE among participants who did and did not have evidence of previous SARS-CoV-2 infection
141 at any point before the study start. We also assessed the combined protective effect of vaccination and
142 prior SARS-CoV-2 infection using four levels of exposures: (i) primary series and no prior infection
143 (reference group), (ii) primary series and prior infection, (iii) booster vaccination without prior infection
144 and (iv) booster vaccination and prior infection. Finally, we assessed the impact of time since vaccination
145 on VE of primary series vaccination compared to unvaccinated.

146

147 *Statistical model*

148 We used Cox proportional hazards models to estimate VE as $(1 - \text{adjusted hazard ratio}) * 100$; therefore all
149 reported VE estimates are adjusted. Vaccination was a time-varying exposure as vaccination status could
150 have changed over time. Thus, the same participant could contribute person-time to more than one
151 exposure category. Calendar time was used as the underlying time in the Cox regression. We used the
152 Schoenfeld residual test to check the proportional hazard assumption. All analyses were performed
153 using R software¹⁸.

154 We calculated unadjusted and adjusted hazard ratio (HR) and estimated VE, including hospital as a fixed
155 effect to account for the multi-site design. We considered the following *a priori* covariates to be added
156 in the multivariable regression model: previous infection, age, sex, household size, any chronic
157 condition. We included the aforementioned confounders that changed the VE estimate by more than
158 5%. Person-time contribution started either on January 1, 2022 or from the start of time at risk for those
159 with prior SARS-CoV-2 infection (90 days after positive test or inferred infection date); it ended at the
160 first occurrence of any of the following events: 1) the day of the SARS-CoV-2 infection, 2) the day of the

161 last weekly questionnaire before complete loss to follow-up, 3) the day of withdrawal from the study, or
162 4) the censor date for the analysis period (31 May 2022). Participants who received a second or third
163 vaccine dose were excluded for 14 days, after which they were considered to be fully immunized with
164 their respective dose and added to the corresponding exposure category. Person-time of participants
165 vaccinated with only one dose was excluded from the analysis. For the secondary analysis that included
166 seroconversion as an outcome, person-time also ended on the day of the last serological result or
167 receipt of an inactivated vaccine. We also performed two sensitivity analyses (Supplemental
168 information).

169 *Ethical considerations*

170 The study protocol was approved by the WHO Research Ethics Review Committee (ERC) (reference
171 number CERC.0097A) and the Albania IPH ERC (reference number 156). This activity was determined to
172 meet the requirements of public health surveillance as defined in 45 CFR 46.102(l) (2) (CDC reference
173 number 0900f3eb81ce0ede). All participants provided written informed consent. The study is registered
174 with clinicaltrials.gov (Identifier NCT04811391).

175 **Results**

176 *Descriptive characteristics*

177 During the analysis period, 1 January – 31 May 2022, 1,462 of the initial 1,504 HCWs (97%) were still
178 enrolled in the study and were included in the analysis. At the start of the follow-up, the median age
179 was 44 years (IQR:34–53), and 1,151 (79%) were female. Overall, 691 (47%) were nurses or midwives,
180 297 (20%) were physicians, 194 (13%) were janitorial staff or food workers, and 280 (19%) had other
181 professions (Table 1). At analysis period start, 1,112 (76%) HCWs had received the primary vaccine series
182 only, 146 (10%) had received a booster dose (third dose), 69 (5%) had received one dose, and 135 (9%)

183 were unvaccinated. Altogether, 959/1,112 (86%) of primary vaccine series were BNT162b2 (Comirnaty,
184 Pfizer-BioNTech), 137 (9%) ChAdOx1-S (Vaxzervria, AstraZeneca) and 11 (1%) CoronaVac (Sinovac Life
185 Sciences). Overall, 143/146 (98%) booster doses were BNT162b2. The median time since receiving the
186 second dose until the start of the analysis period was 289 days (IQR: 210–292 days); for the booster
187 dose, it was 30 days (IQR: 22–45 days) (Figure S2). At analysis start, 1,307 (89%) HCWs had evidence of
188 prior infection, of whom 115 (11%) were infected in the previous 3 months, 836 (57%) were infected 3-
189 12 months earlier, and 356 (24%) were infected more than 12 months prior (Table 1). At the analysis
190 period end, 1070 (73%) participants had received primary series vaccine only, 247 (17%) participants
191 had received a booster dose, 98 (7%) remained unvaccinated and 47 (3%) received only one dose (Table
192 S1). No participants received a second booster dose during the study period. Most booster doses
193 [244/247 (98%)] were BNT162b2, and nearly all participants who received a booster [227/247 (92%)]
194 had received primary series BNT162b2.

195 Unvaccinated HCWs were younger (median age: 35 years) and included more females (89%) compared
196 to HCWs that received either a primary vaccine series (median age: 44 years and 80% female) or a
197 booster dose (median age: 51 years and 57% female). Compared to HCWs who received a primary
198 vaccine series only, boosted HCWs were older (median age: 51 years versus 44 years), more often male
199 (43% versus 20%), had a greater proportion with chronic conditions (28% versus 20%), were more often
200 physicians (56% versus 17%) and were less previously infected (80% versus 90%) (Table 1).

201

202 *Outcomes*

203 The completion rate of the weekly symptom questionnaire was 89% during the follow-up period.
204 Overall, 167 participants reported symptomatic episodes during the study period; two participants

205 reported two symptomatic episodes, ≥ 30 days apart. All participants who reported symptoms had a
206 SARS-CoV-2 PCR or RAT test performed; 104 were positive (94 by PCR and 10 by RAT), and 63
207 participants were negative by PCR or RAT. Among participants included in the analysis, 86 had
208 symptomatic SARS-CoV-2 infections and 107 had asymptomatic infections (55%) (Figure 1B). Of the 86
209 symptomatic infections, 76 were detected by PCR and 10 by RAT. Of the symptomatic infections, 12
210 were among unvaccinated participants, 70 were in participants who had received primary vaccine series,
211 and four were in participants who had received a booster dose (Figure 1A). Most of the 107
212 asymptomatic infections (101 (94%)) were detected through seroconversion (Figure 1B). Combining
213 symptomatic and asymptomatic infections, there were a total of 19 infections among unvaccinated
214 participants, 156 infections in participants with primary vaccine series, and 18 infections in participants
215 who received a booster dose. Almost all symptomatic infections [85/86 (99%)] occurred in January and
216 February, a period when Omicron BA.1 and BA.2 were circulating in Albania (Figure S1B). Overall, 17
217 (22%) samples underwent genomic sequencing, of which 16 (94%) were of BA.1 or BA.2 Omicron
218 sublineage. BA.1 and BA.2 sublineages accounted for more than 96% of sequenced samples from
219 Albania reported to GISAID in January and February 2022¹⁶ (Figure S1B).

220

221 *VE against symptomatic PCR- or RAT-confirmed SARS-CoV-2 infection*

222 VE against symptomatic PCR-confirmed SARS-CoV-2 infection was 34% (95% CI -36;68) for primary
223 vaccine series overall and 26% (95% CI -53;64) for BNT162b2 primary vaccine series (Table 2, Figure 2).
224 Among HCWs with evidence of prior infection, VE of any primary series was 18% (95% CI -83;63) (Table
225 S2). Booster dose VE, compared to unvaccinated HCWs, was 88% (95% CI 39;98) overall and 88% (95% CI
226 38;98) for participants who had received a BNT162b2 booster. The rVE of a booster dose compared to
227 primary series was 57% (95% CI -25;85) for any booster and 56% (95% CI -28;85) for BNT162b2 boosters

228 compared to BNT162b2 primary series. VE estimates against the combined endpoint of symptomatic
229 PCR- or RAT-confirmed infection were slightly higher with narrower confidence intervals (Figure 2, Table
230 2). We could not stratify booster VE according to prior infection status due to the small number of
231 events.

232 *VE against any (asymptomatic and symptomatic) SARS-CoV-2 infection*

233 Primary series VE against any SARS-CoV-2 infection was 19% (95% CI -34;51) overall and 17% (95% CI
234 38;50) for BNT162b2 only. Booster dose VE was 70% (95% CI 19;89) overall and 71% (95% CI 18;90) for
235 BNT162b2 only. (Table 2, Figure 2). Among participants eligible for booster vaccination, the rVE of any
236 first booster dose against any SARS-CoV-2 infection was 36% (95% CI -7;62) and the rVE of BNT162b2
237 booster compared to BNT162b2 primary series was 30% (95% CI -18;59).

238 Compared to HCWs who received the primary vaccine series and had no evidence of prior infection, rVE
239 of a primary vaccine series combined with prior infection was 79% (95% CI 69;85), rVE of booster dose
240 without a prior infection was 47% (95% CI -21;77) and rVE of a booster dose combined with prior
241 infection was 87% (95% CI 73;94) (Table 3).

242 *Change in VE by time since vaccination*

243 For the primary vaccine series, compared to unvaccinated HCWs, VE against symptomatic PCR-
244 confirmed infection was 22% (95% CI -94;69) for participants who had received their second dose within
245 14-179 days and 41% (95% CI -27;73) for those who had received their second doses ≥ 180 days. VE
246 against PCR- or RAT-confirmed symptomatic SARS-CoV-2 infection was 33% (95% CI -57;72) within 14-
247 179 days and 43% (95% CI -12;73) ≥ 180 days (Table 4).

248

249 Discussion

250 Using data from an ongoing cohort study of HCWs in Albania^{12,14}, we found that COVID-19 booster dose
251 VE against symptomatic SARS-CoV-2 infection during a period of Omicron BA.1 and BA.2 predominance
252 was high, at 88%. Conversely, primary vaccine series VE was lower (34%) with low precision. In our
253 cohort, only 17% of HCWs had received a booster dose at the end of the follow-up period, and as of
254 mid-January 2023 only 20% of all HCWs in Albania had received a COVID-19 booster dose⁴. Our high
255 booster VE findings, which to our knowledge reflect the first published booster dose VE results in
256 Southeast Europe, provide evidence to support increased uptake of booster doses among HCWs in
257 Albania.

258 The high booster dose VE against symptomatic infection, reflecting mainly BNT162b2 booster doses
259 given within one month before the start of follow-up, is slightly higher than findings from studies in the
260 United Kingdom¹¹ and Qatar¹⁹, which found recently administered BNT162b2 booster VE of 67% and
261 52%, respectively, against symptomatic Omicron BA.1 and BA.2 infection, with confidence intervals that
262 overlap with those from our study. We also found that rVE was 57% for booster dose compared to
263 HCWs who had received the primary vaccine series a median time of 10 months prior to follow-up. The
264 95% confidence intervals around rVE estimate were wide, with lower bounds that crossed zero. The
265 limited precision of our VE estimates may reflect the relatively small number of events in this analysis.
266 Studies of booster dose rVE against symptomatic Omicron infection in the US²⁰ and Qatar²¹ found low to
267 moderate VE, but rVE was much higher against severe outcomes such as hospitalization and death.

268 In our study, we found that primary vaccine series provided low VE (34%) against symptomatic Omicron
269 infection, although precision was low due to small numbers. This estimate differs from the higher
270 primary series VE estimate we previously found against symptomatic infection during a Delta-
271 predominant period (67%) in the same cohort¹⁴. In our study, median time since receiving the second

272 dose was almost 10 months; therefore, in addition to the increased immune escape of Omicron, waning
273 of vaccine immunity likely contributed to low primary series VE. Waning VE against symptomatic
274 Omicron infection has been shown in other studies.⁹ In the UK¹¹, BNT162b2 VE dropped from 66% in the
275 first month after completion of the primary series to 9% six months after. In our study, we could not
276 observe significant waning primary series immunity, likely due to the low power secondary to the low
277 number of events.

278

279 We found that VE was highest among individuals who were both boosted and had prior SARS-CoV-2
280 infection. These findings are consistent with many published studies that have demonstrated the
281 benefits of hybrid immunity,²² and support the Albanian Ministry of Health and Social Protection
282 recommendations that individuals should receive a primary vaccine series regardless of prior infection
283 history, and that HCWs and other priority populations should receive a booster even if they were
284 previously infected. This message is particularly important in the context of populations with high rates
285 of previous infection; a study in the UK reported lower vaccine acceptance among individuals who were
286 previously infected and thought the vaccine would no longer be useful²³.

287 This study has several strengths. First, regular serological testing of HCWs allowed us to detect
288 seroconversions, infer asymptomatic infections and estimate VE against any SARS-CoV-2 infection.
289 Serology testing also increased our sensitivity in detecting prior infection. Additional strengths of the
290 study are its prospective cohort design and the very high retention rate of the participants after one
291 year of follow-up. Also, the completion rate of the weekly symptom questionnaire remained high during
292 the follow-up period, and all participants with symptoms were tested for SARS-CoV-2.

293 Our study has several limitations. Due to the high coverage of the primary vaccine series in our cohort,
294 only a small number of unvaccinated HCWs were available for a comparison group, and this group may
295 have been different from vaccinated participants with respect to their exposures to SARS-CoV-2 and
296 disease risk²⁵. To overcome this limitation, we also calculated relative VE of booster dose compared to
297 primary vaccine series. In addition, our study was not powered to estimate VE against severe but rare
298 outcomes like hospitalisation or death. Other studies have shown high, durable primary series VE
299 against severe outcomes during Omicron for BNT162b2^{9,10}. Although we were able to detect prior
300 infections through multiple testing platforms, we were not able to analyse time since previous infection.
301 We could not confirm through WGS that all positive participants were infected with BA.1 or BA.2 SARS-
302 CoV-2 Omicron sublineage. There were limited molecular surveillance data from Albania from the first
303 two weeks of January 2022. Finally, because of the low number of events and the relatively low VE,
304 some of our VE estimates had wide confidence intervals and overlapped zero.

305 In our cohort study of Albanian HCWs we found that a monovalent COVID-19 booster dose offered
306 better protection against symptomatic SARS-CoV-2 infection compared to primary vaccine series during
307 a period of BA.1/BA.2 Omicron circulation. These findings underscore the importance of the Albanian
308 Ministry of Health and Social Protection recommendation that all HCWs should receive a booster dose
309 six months following receipt of their primary vaccine series. Our results, which reflect the first locally
310 generated booster VE data, could be communicated to Albanian HCWs in order to decrease vaccine
311 complacency and increase booster uptake. Our findings could be further generalised and used to
312 promote booster dose uptake among HCWs in neighbouring countries in Southeast Europe and in the
313 general population, where booster uptake remains low.

314

315

316 *Acknowledgments*

317 Jörn Beheim-Schwarzbach, Victor M. Corman, and Terry C. Jones (Institute of Virology, Charité-
318 Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt – Universität zu
319 Berlin, and Berlin Institute of Health, Berlin, Germany; and German Centre for Infection Research (DZIF),
320 partner site Charité, Berlin, Germany); Marta Valenciano and Alain Moren (Epiconcept, France).

321

322 *Disclaimer*

323 The findings and conclusions in this report are those of the author(s) and do not necessarily represent
324 the views of the Centers for Disease Control and Prevention. The authors affiliated with the World
325 Health Organization (WHO) are alone responsible for the views expressed in this publication and they do
326 not necessarily represent the decisions or policies of the WHO.

327 *Author contributions*

328 SB, MAK and RP conceived the cohort study on which this analysis is based; IP, IH, JS, AF, RD, AV, MK,
329 MAK, and SB planned and implemented the study, including development of study protocols, data
330 quality checks and acquisition of data; IF, MAK, and SB conceived the article; IF drafted the manuscript
331 and performed the literature search. MYRC performed the data analysis with support from EK. JS, MYRC,
332 and EK directly accessed and verified the raw data and take responsibility for the integrity and accuracy
333 of the analyses. IH, BM, and CD performed lab analysis of study samples. All authors contributed to the
334 interpretation of the results and critically revised the manuscript. All authors had full access to all the
335 data reported in the study and accept responsibility to submit the paper for publication.

336

337 *Financial statement*

338 This study was funded by Task Force for Global Health and World Health Organisation Regional Office
339 for Europe.

340

341 Conflict of interest

342 None of the authors have conflict of interest.

343

344 This work has been presented as oral presentation at European Scientific Conference on Applied

345 Infectious Disease Epidemiology in November 2022, Stockholm, Sweden.

346 **References**

- 347 1 Gómez-Ochoa SA, Franco OH, Rojas LZ, *et al.* COVID-19 in Health-Care Workers: A Living
348 Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and
349 Outcomes. *Am J Epidemiol* 2021; **190**: 161–75.
- 350 2 Smallwood N, Harrex W, Rees M, Willis K, Bennett CM. COVID-19 infection and the broader
351 impacts of the pandemic on healthcare workers. *Respirology* 2022; **27**: 411–26.
- 352 3 Shah AS V, Gribben C, Bishop J, *et al.* Effect of Vaccination on Transmission of SARS-CoV-2. *N Engl*
353 *J Med* 2021; **385**: 1718–20.
- 354 4 WHO Regional Office for Europe. WHO/Europe COVID-19 Vaccine Programme Monitor.
355 https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/.
- 356 5 International Vaccine Access Center (IVAC). Johns Hopkins Bloomberg School of Public Health,
357 VIEW-hub. www.view-hub.org. (accessed Sept 2, 2023).
- 358 6 Clemens J, Aziz AB, Tadesse BT, Kang S, Marks F, Kim J. Evaluation of protection by COVID-19
359 vaccines after deployment in low and lower-middle income countries. *eClinicalMedicine* 2022;
360 **43**. DOI:10.1016/j.eclinm.2021.101253.
- 361 7 Lino A, Cardoso MA, Martins-Lopes P, Gonçalves HMR. Omicron – The new SARS-CoV-2
362 challenge? *Rev Med Virol* 2022; **32**: 1–11.
- 363 8 Neville S, Dombey D, Ghiglione D. Omicron sparks European health staff shortages but spares
364 ICUs. *Financ. Times*. 2022.
- 365 9 Higdon MM, Baidya A, Walter KK, *et al.* Duration of effectiveness of vaccination against COVID-19
366 caused by the omicron variant. *Lancet Infect Dis* 2022; **22**: 1114–6.
- 367 10 Kirsebom FCM, Andrews N, Stowe J, *et al.* COVID-19 vaccine effectiveness against the omicron
368 (BA.2) variant in England. *Lancet Infect Dis* 2022; **22**: 931–3.
- 369 11 Andrews N, Stowe J, Kirsebom F, *et al.* Covid-19 Vaccine Effectiveness against the Omicron
370 (B.1.1.529) Variant. *N Engl J Med* 2022; **386**: 1532–46.
- 371 12 Sridhar S, Fico A, Preza I, *et al.* COVID-19 vaccine effectiveness among healthcare workers in
372 Albania (COVE-AL): Protocol for a prospective cohort study and cohort baseline data. *BMJ Open*
373 2022; **12**: 1–9.
- 374 13 Jorgensen P, Schmid A, Sulo J, *et al.* Factors associated with receipt of COVID-19 vaccination and
375 SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021–June
376 2022): secondary analysis of a prospective cohort study. *Lancet Reg Heal – Eur* 2023; published
377 online March 8. DOI:10.1016/j.lanepe.2023.100584.

- 378 14 Rubin-Smith J, Rojas Castro MY, Preza I, *et al.* Primary Series COVID-19 Vaccine Effectiveness
379 Among Health Care Workers in Albania, February–December 2021. *Available SSRN*
380 <https://ssrn.com/abstract=4282932> or <http://dx.doi.org/102139/ssrn4282932>.
- 381 15 Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international community
382 of software platform partners. *J Biomed Inform* 2019; **95**: 103208.
- 383 16 Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality.
384 *Eurosurveillance* 2017; **22**. DOI:<https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494>.
- 385 17 Wajnberg A, Mansour M, Leven E, *et al.* Humoral response and PCR positivity in patients with
386 COVID-19 in the New York City region, USA: an observational study. *The Lancet Microbe* 2020; **1**:
387 e283–9.
- 388 18 R Foundation for Statistical Computing. R Core Team (2018). R: A language and environment for
389 statistical computing. <https://www.r-project.org/>.
- 390 19 Chemaitelly H, Ayoub HH, AlMukdad S, *et al.* Duration of mRNA vaccine protection against SARS-
391 CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. *Nat Commun* 2022; **13**: 1–12.
- 392 20 Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative Vaccine Effectiveness of a Severe Acute
393 Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron
394 Variant. *Clin Infect Dis* 2022; **75**: 2161–8.
- 395 21 Abu-Raddad LJ, Chemaitelly H, Ayoub HH, *et al.* Effect of mRNA Vaccine Boosters against SARS-
396 CoV-2 Omicron Infection in Qatar. *N Engl J Med* 2022; **386**: 1804–16.
- 397 22 Bobrovitz N, Ware H, Ma X, *et al.* Protective effectiveness of prior SARS-CoV-2 infection and
398 hybrid immunity against Omicron infection and severe disease: a systematic review and meta-
399 regression. *Lancet Infect Dis* 2023; **22**. DOI:10.1016/S1473-3099(22)00801-5.
- 400 23 Stead M, Jessop C, Angus K, *et al.* National survey of attitudes towards and intentions to
401 vaccinate against COVID-19: implications for communications. *BMJ Open* 2021; **11**.
402 DOI:10.1136/bmjopen-2021-055085.
- 403 24 Tsang NNY, So HC, Cowling BJ, Leung G, Ip DKM. Effectiveness of BNT162b2 and CoronaVac
404 COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron
405 BA.2 in Hong Kong. *SSRN Electron J* 2022; **3099**: 1–14.
- 406 25 World Health Organization. Evaluation of COVID-19 vaccine effectiveness in a changing landscape
407 of COVID-19 epidemiology and vaccination. 2021
408 [https://apps.who.int/iris/bitstream/handle/10665/363344/WHO-2019-nCoV-vaccine-](https://apps.who.int/iris/bitstream/handle/10665/363344/WHO-2019-nCoV-vaccine-effectiveness-VE-evaluations-2022.1-eng.pdf)
409 [effectiveness-VE-evaluations-2022.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/363344/WHO-2019-nCoV-vaccine-effectiveness-VE-evaluations-2022.1-eng.pdf).

410

411


412 **Tables and figures**

413 **Table 1. Demographic and occupational characteristics of health care worker participants by**
 414 **vaccination status on the first day of the follow-up period (n=1462), Albania, 2022**

Characteristics	All Participants (n= 1462)	Unvaccinated (n= 135)	Primary vaccine series (n= 1112)	Booster vaccine (n= 146)
Age, in years, at start of person-time contribution				
Median (IQR)	44 (34-53)	35 (30-46)	44 (34-52)	51 (42-57)
Age group (in years) at start of person-time contribution				
20-29, n (%)	208 (14)	28 (21)	158 (14)	6 (4)
30-39, n (%)	381 (26)	55 (41)	281 (25)	21 (14)
40-49, n (%)	364 (25)	21 (16)	295 (27)	40 (27)
50-59, n (%)	407 (28)	26 (19)	310 (28)	51 (35)
60+, n (%)	102 (7)	5 (4)	68 (6)	28 (19)
Sex				
M, n (%)	311 (21)	15 (11)	223 (20)	63 (43)
F, n (%)	1151 (79)	120 (89)	889 (80)	83 (57)
Hospital				
Tirana, n (%)	905 (62)	91 (67)	670 (60)	94 (64)
Durres, n (%)	297 (20)	18 (13)	242 (22)	33 (23)
Fier, n (%)	260 (18)	26 (19)	200 (18)	19 (13)
Any chronic condition*^				
No, n (%)	1175 (80)	117 (87)	893 (80)	105 (72)
Yes, n (%)	287 (20)	18 (13)	219 (20)	41 (28)
Occupation/Role in hospital*				
Physician, n (%)	297 (20)	15 (11)	191 (17)	82 (56)
Nurse or midwife, n (%)	691 (47)	64 (47)	552 (50)	49 (34)
Janitorial staff or food worker, n (%)	194 (13)	15 (11)	164 (15)	6 (4)
Other, n (%)	280 (19)	41 (30)	205 (18)	9 (6)
Patient-facing role*				
Yes, n (%)	1394 (95)	120 (89)	1064 (96)	143 (98)
No, n (%)	68 (5)	15 (11)	48 (4)	3 (2)
Hands-on care*				
No, n (%)	582 (40)	59 (44)	431 (39)	53 (36)
Yes, n (%)	880 (60)	76 (56)	681 (61)	93 (64)
Household size* (n=1407)				
1-3, n (%)	557 (40)	55 (42)	408 (38)	66 (46)
4-5, n (%)	733 (52)	64 (49)	571 (54)	67 (47)
6+, n (%)	117 (8)	11 (8)	88 (8)	11 (8)
COVID-19 vaccination status(n=1325)				
Unvaccinated, n (%)	135 (10)	135 (100)		
BNT162b2 - 1 dose, n (%)	48 (4)			
BNT162b2 - 2 dose, n (%)	959 (72)		959 (86)	
BNT162b2 - 3 dose, n (%)	143 (11)			143 (98)
ChAdOx-S – 2 dose, n (%)	137 (9)		137 (12)	
CoronaVac - 2 doses, n (%)	11 (<1)		11 (1)	
Other, n (%)	29 (2)		5 (<1)	3 (2)
Number of days between 2nd dose and start of person-time contribution (n=1258)				


Median (IQR)	289 (210-294)		289 (210-292)	292 (288-296)
Number of days between 3rd dose and start of person-time contribution (n=146)				
Median (IQR)	30 (22-46)			30 (22-46)
Previous Infection (PCR+, RAT+ or seroconversion)				
No, n (%)	155 (11)	8 (6)	114 (10)	29 (20)
Yes, n (%)	1307 (89)	127 (94)	998 (90)	117 (80)
Time from ** previous infection (PCR+, RAT+, seroconversion) to start of follow-up period+ (n=1307)				
No previous infection, n (%)	155 (11)	8 (6)	114 (10)	29 (20)
Median number of days (IQR)	338 (313-379)	325 (291-390)	338 (316-375)	339 (297-396)
<3 months, n (%)	115 (8)	15 (11)	85 (8)	10 (7)
3-12 months, n(%)	836 (57)	72 (53)	646 (58)	75 (51)
12 or more months, n (%)	356 (24)	40 (30)	267 (24)	32 (22)

415 * Information collected at study enrolment (February-May 2021)
 416 **Onset of symptoms, swab date or inferred infection date to the start of person-time contribution
 417 ^chronic conditions: diabetes, hypertension, immunosuppression, cancer, autoimmune disease, lung disease,
 418 kidney disease, liver disease
 419
 420
 421
 422



423
 424
 425
 426 **Figure 1. SARS-CoV-2 infections among HCWs by week, January 1 – May 31, 2022**

427 A – Symptomatic SARS-CoV-2 infections stratified by vaccination status and type of confirmatory test, by week; B –
 428 all SARS-CoV-2 infections stratified by presence of symptoms, by week
 429
 430
 431
 432
 433



434
 435 **Figure 2. COVID-19 vaccine effectiveness estimates of primary vaccine series and booster dose against**
 436 **PCR-confirmed symptomatic SARS-CoV-2 infection (left), PCR- or RAT-confirmed symptomatic SARS-**
 437 **CoV-2 infection (middle) and any (asymptomatic or symptomatic) SARS-CoV-2 infection confirmed by**
 438 **PCR, RAT or seroconversion (right)**
 439 Dot – point estimate; lines – 95% confidence interval; blue – Primary series VE; violet – booster dose VE

Table 2. COVID-19 vaccine effectiveness of primary vaccine series and booster dose against SARS-CoV-2 infection during a period of Omicron (BA.1 and BA.2) predominance, and relative vaccine effectiveness of booster dose compared to primary vaccine series, Albania, January 1 – May 31, 2022

			Number of HCWs	Total person-time (days)	PCR-confirmed infection	RAT-confirmed infection	Sero-conversion	All infections	Unadjusted HR (95% CI)	Adjusted HR**(95% CI)	VE (95% CI)
Primary vaccine series vaccine effectiveness											
Symptomatic infection	PCR	Unvaccinated	130	12736	10			10	Ref	Ref	Ref
		Primary series - any vaccine	1124	139274	62			62	0.68 (0.35; 1.32)	0.66 (0.32; 1.36)	34 (-36; 68)
		Unvaccinated	130	60745	10			10	Ref	Ref	Ref
	PCR and RAT	Primary series - BNT162b2	972	521880	57			57	0.75 (0.38; 1.47)	0.74 (0.36; 1.53)	26 (-53; 64)
		Unvaccinated	130	12736	10	2		12	Ref	Ref	Ref
		Primary series - any vaccine	1124	139274	62	8		70	0.62 (-0.34; 1.16)	0.60 (0.31; 11.8)	40 (-18; 69)
Any infection	PCR and RAT	Unvaccinated	130	12736	10	2		12	Ref	Ref	Ref
		Primary series - any vaccine	1124	139274	62	8		70	0.62 (-0.34; 1.16)	0.60 (0.31; 11.8)	40 (-18; 69)
		Unvaccinated	130	12736	10	2		12	Ref	Ref	Ref
		Primary series - BNT162b2	972	119852	57	8		65	0.69 (0.37; 1.29)	0.67 (0.34; 1.32)	33 (-32; 66)
Any infection	PCR and RAT	Unvaccinated	129	12102	10	3	6	19	Ref	Ref	Ref
		Primary series - any vaccine	1108	128525	63	11	82	156	0.86 (0.53; 1.39)	0.81 (0.49; 1.34)	19 (-34; 51)
		Unvaccinated	129	12102	10	3	6	19	Ref	Ref	Ref
		Primary series - BNT162b2	972	112800	59	10	66	135	0.86 (0.53; 1.40)	0.83 (0.50; 1.38)	17 (-38; 50)
Booster dose vaccine effectiveness											
Symptomatic infection	PCR	Unvaccinated	130	12736	10			10	Ref	Ref	Ref
		Booster dose - any vaccine	240	29219	4			4	0.27 (0.08; 0.91)	0.12 (0.02; 0.62)	88 (39; 98)
		Unvaccinated	130	12736	10			10	Ref	Ref	Ref
	PCR and RAT	Booster dose - BNT162b2	221	27343	4			4	0.28 (0.08; 0.95)	0.12 (0.02; 0.63)	88 (38; 98)
		Unvaccinated	130	12736	10	2		12	Ref	Ref	Ref
		Booster dose - any vaccine	240	29219	4	0		4	0.22 (0.07; 0.72)	0.09 (0.02; 0.44)	91 (56; 98)
Any infection	PCR and RAT	Unvaccinated	130	12736	10	2		12	Ref	Ref	Ref
		Booster dose - BNT162b2	221	27343	4	0		4	0.23 (0.07; 0.75)	0.09 (0.02; 0.45)	91 (56; 98)
		Unvaccinated	129	57322	10	3	6	19	Ref	Ref	Ref
		Booster dose - any vaccine	228	118247	5	0	13	18	0.55 (0.28; 1.10)	0.30 (0.11; 0.81)	70 (19; 89)
Any infection	PCR and RAT	Unvaccinated	129	57322	10	3	6	19	Ref	Ref	Ref
		Booster dose - BNT162b2	215	115050	5	0	13	18	0.57 (0.29; 1.13)	0.31 (0.12; 0.82)	69 (18; 88)
Relative vaccine effectiveness*											
Symptomatic infection	PCR	Primary series - any vaccine	1110	541839	51			51	Ref	Ref	Ref
		Booster dose - any vaccine	240	130487	4			4	0.46 (0.16; 1.29)	0.44 (0.15; 1.25)	57 (-25; 85)
		Primary series - BNT162b2	955	113450	45			45	Ref	Ref	Ref
		Booster dose - BNT162b2	221	27343	4			4	0.46 (0.16; 1.31)	0.44 (0.15; 1.28)	56 (-28; 85)
	PCR and RAT	Primary series - any vaccine	955	488719	51	8		59	Ref	Ref	Ref
		Booster dose - any vaccine	221	125319	4	0		4	0.40 (0.14; 1.12)	0.39 (0.14; 1.11)	61 (-11; 86)
		Primary series - BNT162b2	955	488719	45	8		53	Ref	Ref	Ref
		Booster dose - BNT162b2	221	125319	4	0		4	0.40 (0.14; 1.13)	0.39 (0.14; 1.12)	61 (-12; 86)
Any infection	PCR and RAT	Primary series - any vaccine	1083	120282	51	11	76	138	Ref	Ref	Ref
		Booster dose - any vaccine	228	26621	5	0	13	18	0.71 (0.43; 1.17)	0.64 (0.38; 1.07)	36 (-7; 62)
		Primary series - BNT162b2	946	106021	46	10	62	118	Ref	Ref	Ref

Booster dose - BNT162b2	215	25308	5	0	13	18	0.77 (0.47; 1.27)	0.70 (0.41; 1.18)	30 (-18; 59)
-------------------------	-----	-------	---	---	----	----	-------------------	-------------------	--------------

*Participants eligible for booster dose

**HR were adjusted for: hospital site, time since previous infection, age, sex and household size

446

Table 3. Relative Vaccine effectiveness of booster dose compared to primary vaccine series against any SARS-CoV-2 infection during a period of Omicron (BA.1 and BA.2) predominance, stratified by previous COVID-19 infection, Albania, January 1 – May 31, 2022

	Number of HCWs	Total person-time (days)	PCR-confirmed infection	RAT-confirmed infection	Sero-conversion	All infections	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	VE in % (95% CI)
Any vaccine*									
Vaccinated (2 dose - only)/no previous infection	110	9605	7	1	36	44	Ref	Ref	Ref
Vaccinated (2 dose - only)/previous infection	973	110677	44	10	40	94	0.22 (0.16; 0.32)	0.21 (0.15; 0.31)	79 (69; 85)
Vaccinated (3 dose)/no previous infection	34	3899	1	0	7	8	0.51 (0.23; 1.09)	0.53 (0.23; 1.21)	47 (-21; 77)
Vaccinated (3 dose)/previous infection	194	22722	4	0	6	10	0.13 (0.06; 0.27)	0.13 (0.06; 0.27)	87 (73; 94)
BNT162b2*									
Vaccinated (2 dose - only)/no previous infection	93	8511	5	1	28	34	Ref	Ref	Ref
Vaccinated (2 dose - only)/previous infection	853	97510	41	9	34	84	0.25 (0.17; 0.38)	0.25 (0.17; 0.37)	75 (63; 83)
Vaccinated (3 dose)/no previous infection	33	3774	1	0	7	8	0.61 (0.27; 1.35)	0.64 (0.27; 1.50)	36 (-50; 73)
Vaccinated (3 dose)/previous infection	182	21534	4	0	6	10	0.16 (0.07; 0.35)	0.16 (0.07; 0.36)	84 (64; 93)

HR were adjusted for: hospital site, age and sex

Table 4. Vaccine effectiveness against SARS-CoV-2 infection during a period of Omicron (BA.1 and BA.2) predominance by time since receiving primary vaccine series, Albania, January 1 – May 31, 2022

	Number of HCWs	Total person-time (days)	PCR-confirmed infection	RAT-confirmed infection	All infections	Unadjusted HR % (95%CI)	Adjusted HR % (95%CI)	Adjusted VE % (95%CI)
Symptomatic SARS-CoV-2-infections detected by PCR by time since vaccination								
Unvaccinated	130	12736	10		10	Ref	Ref	Ref
2nd dose 14-179 days ago (any vaccine)	239	19124	13		13	0.92 (0.39; 2.19)	0.78 (0.31; 1.94)	22 (-94; 69)
2nd dose 180+ days ago (any vaccine)	1018	120150	49		49	0.64 (0.31; 1.35)	0.59 (0.27; 1.27)	42 (-27; 73)
Symptomatic SARS-CoV-2 infection detected by PCR or RAT by time since vaccination								
Unvaccinated	130	12736	10	2	12	Ref	Ref	Ref
2nd dose 14-179 days ago (any vaccine)	239	14031	13	0	13	0.76 (0.33; 1.73)	0.67 (0.28; 1.57)	34 (-57; 72)
2nd dose 180+ days ago (any vaccine)	1018	105821	49	8	57	0.59 (0.32; 1.12)	0.57 (0.27; 1.13)	43 (-13; 73)

HR were adjusted for: hospital site, previous infection, age and sex

